The Asia Pacific Diabetes Pen Market Size is expected to reach USD 1435.16 Million by 2030 at 2.90% CAGR during the forecast period 2022-2030.
Diabetes is a highly concerning and prevalent chronic disease across the globe. The prevalence and the subsequent impact upon the affected patients have made leading researchers, developers, scientists, and innovators to come up with a new and innovative product to tackle the same.
Insulin is a hormone that is produced by the help of pancreas. However, during diabetes, the pancreas fails to produce the requisite insulin for the body. In order to inject insulin, a diabetes pen is required for the treatment of diabetes. The product consists of an insulin cartridge, one which is either integrated or bought separately, and a dial that is used to measure the dosage level. This is used with disposable pen needles that helps deliver the dosage. The high intake of sugar and carbs, increasing cases of obesity, and the evolving consumer lifestyle are some of the major factors spreading the prevalence of this disease.
Competitive Landscape
The global diabetes pen market comprises numerous players, including Becton, Dickinson and Company (U.S.), AstraZeneca (U.K),Teruma Medical Corporation (Japan), F. Hoffman La Roche AG (Switzerland), Greinier Bio One International GmBH (U.S.), Bayer Cropscience Ltd. (Germany), and HTL STREFA SA (Poland).
Regional Analysis
The global diabetes pen market is geographically segmented into the following four major regions: Asia Pacific, Europe, Americas, and the Middle East Africa.
North America holds the largest share of the global diabetes pen market. Moreover, the region is expected to garner consistent growth and expansion in the near future. The factor influencing this positive growth trajectory of the market is the presence of a large diabetic population, improved awareness of the consumers, and the reimbursement policies for diabetes management. Add to this, continual advancements in diabetes pen technology and increasing research and development activities are also expected to drive the regional market of North America.
Europe is the second-largest market in the global landscape and is expected to witness negligible growth during the forecast period. Herein, the growth of the region is attributed to the extensive usage of diabetes pen in the United Kingdom.
The Asia Pacific region is another key market in the global scenario. The region is positioned to grow in the fastest manner and cement its position as one of the leading regional markets over the forecast period. The Asia Pacific region is driven by the large pool of patients, improving awareness among the consumers, evolving healthcare infrastructure, and the increasing expenditure in healthcare. Additionally, new and innovative product launches and supportive regulations imposed by the government help speed up the market growth in this region. Countries like India, China, and Japan are expected to contribute majorly to the success of the market.
India is known to have a major percentage of people suffering from diabetes. Due to the rising old-age population with diabetic conditions and an irregular change in sugar levels, India is contributing significantly to the diabetes pen market.
Lastly, the Middle East Africa region is expected to attain steady and decent growth owing to the increasing awareness among the consumers concerning lifestyle-based diseases and the emergence of an influx of preventive measures to tackle the elevated sugar levels of individuals.
Market Segmentation
The global diabetes pen market segmentation is classified on the basis of usage, distribution/sales channel, and product type.
By distribution channel, the market comprises of online sales, retail pharmacy, hospital pharmacy, and diabetes clinics.
By product type, the market divides into insulin pen needles and insulin pens.
By usage, the market segments into disposable pens and reusable pens.
The players are innovating with new products and consistently conducting research and development activities to edge past the competition and strengthen their global reach.
Feb 18th, 2019, Glooko, a diabetics data management organization, announced that its latest Novo Nordisk connected insulin pens will be connected to the diasend platform. The soon-to-be launched devices will be Novo Nordisks NovoPen 6 and NovoPen Echo Plus.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: [email protected]
